Pure Bioscience(PURE)
$0.06-0.00 (-1.67%)
PURE
Pure Bioscience financials statements
$0.06
At close:-0.00 (-1.67%)
Want to see PURE full AI Analyst Report?
Pure Bioscience (PURE) Ratios
47 Followers
Pure Bioscience Ratios
PURE's free cash flow for Q4 2026 was $-414.00K. For the 2026 fiscal year, PURE's free cash flow was increased by $0.00 and operating cash flow was $-414.00K. See a summary of the company’s cash flow.
| Ratios | Jul 26 | Jul 25 | Jul 24 | Jul 23 | Jul 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.27 | 1.12 | 1.10 | 3.02 | 6.72 |
| Quick Ratio | 0.23 | 0.97 | 1.02 | 2.85 | 6.41 |
| Cash Ratio | 0.13 | 356.08 | 0.48 | 2.06 | 5.90 |
| Solvency Ratio | -0.33 | -0.39 | -0.87 | -2.48 | -5.71 |
| Operating Cash Flow Ratio | -0.40 | -2.15 | -3.45 | -6.16 | -4.21 |
| Short-Term Operating Cash Flow Coverage | -0.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -6.41M | $ -5.13M | $ -2.88M | $ 51.00K | $ 3.29M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 5.53 | 0.49 | 3.61 | 0.56 | 0.00 |
| Debt-to-Equity Ratio | -1.03 | -0.10 | -1.03 | 3.75 | 0.00 |
| Debt-to-Capital Ratio | 32.52 | -0.11 | 34.69 | 0.79 | 0.00 |
| Long-Term Debt-to-Capital Ratio | -1.01 | -0.11 | 34.69 | 0.79 | 0.00 |
| Financial Leverage Ratio | -0.19 | -0.21 | -0.29 | 6.71 | 1.15 |
| Debt Service Coverage Ratio | -0.55 | -7.02 | -19.66 | -273.57 | -545.33 |
| Interest Coverage Ratio | -5.12 | -7.60 | -20.20 | -281.64 | -570.83 |
| Debt to Market Cap | 0.89 | 0.05 | 0.33 | 0.11 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.01 | 0.03 | 0.01 | 0.00 |
| Net Debt to EBITDA | -2.90 | 158.95 | -0.85 | 0.02 | 1.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.20% | 59.17% | 58.69% | 51.73% | 53.97% |
| EBIT Margin | -89.86% | -95.37% | -162.76% | -210.28% | -188.07% |
| EBITDA Margin | -89.86% | -95.28% | -155.22% | -204.05% | -176.58% |
| Operating Profit Margin | -89.86% | -103.18% | -159.50% | -210.07% | -184.84% |
| Pretax Profit Margin | -107.12% | -108.95% | -170.66% | -211.03% | -188.40% |
| Net Profit Margin | -107.12% | -108.95% | -170.66% | -211.03% | -188.72% |
| Continuous Operations Profit Margin | -107.12% | -108.95% | -170.66% | -211.03% | -188.40% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.17% |
| EBT Per EBIT | 119.20% | 105.59% | 106.99% | 100.46% | 101.93% |
| Return on Assets (ROA) | -208.13% | -226.75% | -409.54% | -217.04% | -77.99% |
| Return on Equity (ROE) | 38.80% | 46.89% | 116.97% | -1456.25% | -89.46% |
| Return on Capital Employed (ROCE) | 65.54% | -1893.33% | -3683.53% | -304.95% | -87.62% |
| Return on Invested Capital (ROIC) | -1026.11% | -20.45% | -3683.53% | -304.95% | -87.62% |
| Return on Tangible Assets | -208.13% | -226.75% | -409.54% | -217.04% | -77.99% |
| Earnings Yield | -33.31% | -23.88% | -37.53% | -41.83% | -19.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.94 | 4.65 | 6.59 | 6.59 | 9.22 |
| Payables Turnover | 1.21 | 1.15 | 1.35 | 2.15 | 1.75 |
| Inventory Turnover | 5.14 | 6.38 | 14.48 | 10.30 | 4.77 |
| Fixed Asset Turnover | 289.75 | 0.20 | 151.00 | 8.49 | 2.99 |
| Asset Turnover | 1.94 | 2.08 | 2.40 | 1.03 | 0.41 |
| Working Capital Turnover Ratio | -1.51 | 24.33 | 3.43 | 0.86 | 0.67 |
| Cash Conversion Cycle | -178.11 | -182.49 | -189.87 | -79.14 | -92.63 |
| Days of Sales Outstanding | 52.59 | 78.57 | 55.41 | 55.42 | 39.59 |
| Days of Inventory Outstanding | 71.01 | 57.25 | 25.20 | 35.45 | 76.59 |
| Days of Payables Outstanding | 301.71 | 318.31 | 270.49 | 170.01 | 208.82 |
| Operating Cycle | 123.61 | 135.82 | 80.61 | 90.87 | 116.19 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 |
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -99.33 | -29.85 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -99.33 | -29.85 |
| Operating Cash Flow Coverage Ratio | -0.26 | -3.85 | -0.86 | -3.21 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.75 | -0.92 | -1.29 | -1.75 | -1.30 |
| Free Cash Flow Yield | -23.32% | -20.06% | -28.35% | -34.97% | -14.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.00 | -4.20 | -2.66 | -2.39 | -5.00 |
| Price-to-Sales (P/S) Ratio | 3.22 | 4.56 | 4.55 | 5.04 | 9.44 |
| Price-to-Book (P/B) Ratio | -1.16 | -1.96 | -3.12 | 34.81 | 4.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.29 | -4.99 | -3.53 | -2.86 | -7.00 |
| Price-to-Operating Cash Flow Ratio | -4.29 | -4.99 | -3.53 | -2.89 | -7.24 |
| Price-to-Earnings Growth (PEG) Ratio | 6.43 | 0.15 | 0.17 | 0.25 | -0.10 |
| Enterprise Value Multiple | -6.47 | 154.16 | -3.78 | -2.45 | -4.31 |
| Enterprise Value | 13.49M | -323.43M | 11.53M | 9.40M | 14.11M |
| EV to EBITDA | -6.47 | 154.16 | -3.78 | -2.45 | -4.31 |
| EV to Sales | 5.82 | -146.88 | 5.87 | 5.01 | 7.61 |
| EV to Free Cash Flow | -7.76 | 160.51 | -4.55 | -2.84 | -5.65 |
| EV to Operating Cash Flow | -7.76 | 160.51 | -4.55 | -2.87 | -5.84 |
| Tangible Book Value Per Share | -0.05 | -0.05 | -0.03 | 0.00 | 0.04 |
| Shareholders’ Equity Per Share | -0.05 | -0.05 | -0.03 | 0.00 | 0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Net Income Per Share | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.19 | 1.14 | 1.05 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.14 | 0.14 | 0.15 | 0.16 | 0.17 |
| SG&A to Revenue | 1.33 | 1.48 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.08 | 0.07 | 0.11 | 0.17 | 0.31 |
| Income Quality | 0.70 | 0.84 | 0.76 | 0.83 | 0.69 |
Currency in USD

